Identification of potential rbpj-specific inhibitors for blocking notch signaling in breast cancer using a drug repurposing strategy

HIGHLIGHTS

• who: Mengjie Rui et al. from the Department of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang, China have published the research: Identification of Potential RBPJ-Specific Inhibitors for Blocking Notch Signaling in Breast Cancer Using a Drug Repurposing Strategy, in the Journal: Pharmaceuticals 2022, 556 of /2022/
• what: The study demonstrated that fidaxomicin suppressed and may be repurposed for the treatment of breast cancer. The authors demonstrated that fidaxomicin was identified as a potential small_molecule inhibitor of RBPJ, eventually inhibiting Notch signaling in breast cancer cells.
• how: In search of a more effective . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.